How to Handle Dropouts and Protocol Deviations in Clinical Trial Analysis

Dropouts and protocol deviations are almost inevitable in clinical trials. Whether due to patient withdrawal, non-adherence, or procedural inconsistencies, these events can distort the trial results if not properly handled. Regulators like the USFDA and EMA expect clear definitions and pre-specified methods for managing these issues in both the protocol and Statistical Analysis Plan (SAP).

This tutorial explains how to classify, analyze, and report dropouts and protocol deviations in a way that preserves data integrity, ensures regulatory compliance, and supports valid conclusions from your clinical trial.

What Are Dropouts and Protocol Deviations?

Dropouts:

Subjects who discontinue participation before completing the study, often due to adverse events, lack of efficacy, consent withdrawal, or personal reasons.

Protocol Deviations:

Any departure from the approved trial protocol, whether intentional or unintentional, including incorrect dosing, visit window violations, or missing assessments.

Proper classification and documentation of both are required in GMP-compliant studies.

Types of Protocol Deviations

• Major Deviations: Affect the primary endpoint or trial integrity (e.g., incorrect randomization)
• Minor Deviations: Do not impact key trial outcomes (e.g., visit outside window)
• Eligibility Deviations: Inclusion of ineligible subjects
• Treatment Deviations: Non-adherence to investigational product protocol

Major deviations usually exclude subjects from the Per Protocol (PP) analysis set but may remain in the Intent-to-Treat (ITT) set.

Statistical Approaches for Dropouts

1. Intent-to-Treat (ITT) Analysis:

Includes all randomized subjects, regardless of adherence or dropout. This approach preserves randomization benefits and is the gold standard for efficacy trials.

However, missing data due to dropouts must be addressed using methods such as:

• Mixed Models for Repeated Measures (MMRM)
• Multiple Imputation (MI)
• Pattern-Mixture Models
• Last Observation Carried Forward (LOCF) – discouraged for primary analysis

2. Per Protocol (PP) Analysis:

Includes only subjects who adhered strictly to the protocol. This provides a clearer picture of treatment efficacy under ideal conditions.

It is often used as a supportive analysis to ITT and must be predefined in the SAP and CSR.

Handling Protocol Deviations in Analysis

Deviations should be categorized and analyzed for their impact. Best practices include:

• Pre-specify major vs minor deviations in the SAP
• Perform sensitivity analysis excluding subjects with major deviations
• Justify inclusion/exclusion of deviators in each analysis set
• Report all deviations in the CSR by type and frequency

Major deviations that affect endpoints (e.g., missing primary assessments) should typically exclude those subjects from PP analysis.

Estimand Framework and Intercurrent Events

The ICH E9(R1) guideline encourages defining “intercurrent events,” which include dropouts and deviations. These are addressed through different strategies like:

• Treatment Policy: Analyze all randomized subjects regardless of intercurrent events
• Hypothetical: Model the outcome as if the event had not occurred
• Composite: Combine event with outcome into a single endpoint
• Principal Stratum: Restrict analysis to subgroup unaffected by the event

Choosing the right estimand and handling approach is a regulatory expectation and should align with trial registration strategies.

Regulatory Expectations for Dropouts and Deviations

USFDA: Emphasizes transparency in dropout handling and discourages LOCF as a primary method. Requires dropout reasons to be detailed in submission.

EMA: Requires analysis of protocol adherence and impact on efficacy interpretation. Supports multiple sensitivity analyses.

CDSCO: Encourages sponsor accountability in tracking and preventing protocol violations. Dropout management is critical during audits.

Best Practices for Managing Dropouts and Deviations

• Include dropout prevention strategies in the protocol
• Use eCRFs to track deviation type, reason, and impact
• Train sites on protocol adherence and data quality
• Implement real-time deviation monitoring dashboards
• Review deviation reports during interim data reviews

Example Scenario

In a Phase III diabetes trial, 10% of patients dropped out before the Week 24 endpoint. ITT analysis used MMRM to handle missing data, assuming MAR. A per-protocol analysis excluded 6% with major protocol deviations. Sensitivity analyses using pattern-mixture models supported the robustness of findings, as treatment effect remained statistically significant under all assumptions. The FDA approved the submission based on the transparent and well-planned analysis of dropouts and deviations.

Conclusion

Handling dropouts and protocol deviations effectively is essential for the credibility and regulatory acceptance of your clinical trial. Start with proper planning and classification, follow with appropriate statistical handling, and ensure transparent documentation. Using robust ITT and PP analyses, backed by sensitivity analyses and regulatory guidance, helps ensure that your results are reliable, unbiased, and ready for global submission.